Medical Virology is a specialized branch of virology that focuses on the study of viruses and their interactions with the human body, particularly in the context of infectious diseases and public health. It encompasses a wide range of research areas, including viral pathogenesis, epidemiology, diagnosis, treatment, and prevention. Vaccines are a key component of medical virology, as they play a critical role in preventing viral infections and controlling the spread of infectious diseases. Vaccines work by stimulating the body's immune system to recognize and respond to specific viral antigens, priming it to mount a protective immune response upon exposure to the virus.
Medical virologists play a central role in the development and evaluation of vaccines, from initial vaccine design and preclinical testing to clinical trials and post-marketing surveillance. They study the structure and function of viruses to identify potential vaccine targets, such as viral proteins or surface molecules, and develop strategies to induce protective immunity. Vaccines have been developed for a wide range of viral diseases, including measles, mumps, rubella, polio, influenza, hepatitis, human papillomavirus (HPV), and COVID-19. These vaccines have been highly successful in reducing the burden of infectious diseases and preventing outbreaks, saving millions of lives worldwide.
Medical virologists also play a crucial role in vaccine safety monitoring and surveillance, ensuring that vaccines are safe and effective for use in the population. They conduct studies to assess the safety and efficacy of vaccines, monitor adverse events following vaccination, and investigate vaccine failures or breakthrough infections. In addition to vaccine development, medical virologists study the natural history of viral infections, including how viruses spread, replicate, and cause disease in humans. They use advanced diagnostic techniques, such as molecular assays and serological tests, to detect and identify viral pathogens and monitor the progression of viral infections.
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey